RetinAI Discovery® UNITY is designed to improve the healthcare decision process in Ophthalmology. It is one platform for unification and structuring of data in a single ecosystem.
By unlocking the power of data, Discovery UNITY helps pharmaceutical and life sciences build unparalleled disease understanding to help guide and accelerate research and development for better patient care.
Single data platform to manage data from different sources and devices, at scale. Access data anytime from anywhere.
Integrated AI technology to extract insights across datasets for a better understanding of diseases and patient groups.
A data insurance policy. Secured storage and archival only accessible to authorized personnel to provide peace-of-mind to an organization’s precious resource, its data.
RetinAI Discovery is a CE-marked medical device according to the Medical Devices Regulation (EU) 2017/745
and the AI models are CE-marked devices according to Medical Devices Directive 93/42/EEC
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.
Discovery and AI Models are CE-Marked medical devices since April 2020 & December 2020 respectively.